Toujeo Max SoloStar Gets FDA Approval for Patients With Diabetes

Toujeo Max SoloStar is expected to be available in the third quarter of 2018
Toujeo Max SoloStar is expected to be available in the third quarter of 2018

Sanofi announced that the Food and Drug Administration (FDA) has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen that holds 900 Units of Toujeo and provides up to 160 Units per injection. 

Toujeo, a long-acting human insulin analog, is indicated to improve glycemic control in adults with diabetes mellitus. As the Toujeo Max SoloStar pen has a higher capacity and can deliver a maximum dose of up to 160 Units, it can potentially reduce the number of pens used as well as the number of injections needed to deliver the required dose of insulin glargine to patients with diabetes.

Related Articles

Toujeo is already available as 1.5mL SoloStar prefilled pens containing 450 Units in 3-count packs. The new 3mL Toujeo Max SoloStar prefilled pens are anticipated to launch in the 3rd quarter of 2018 as 2-count packs. 

For more information call (800) 633-1610 or visit Toujeo.com.